HAL (France)open access
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del -gating and F508del -residual function genotypes: results from an open-label extension study
Elexacaftor, CFTR, Gating, 0, 1, Residual function, Cystic fibrosis
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 971087
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.